ArticleGynecologic oncology reports2026
Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study investigated immune and gene expression modulation of tumor microenvironment (TME) by oncolytic vaccinia virus Olvi-Vec as an immunotherapy and subsequent clinical impact on platinum sensitivity in ovarian cancer (OC). Results: In the preclinical study, durable antitumor effect was achieved through combination treatment with Olvi-Vec and cisplatin in mouse model of PROC. Cytologic analysis in VIRO-15 showed viral infection and eradication of tumor cells in patients' ascitic fluid. Multiplex IHC analysis demonstrated large influx of CD8+ tumor-infiltrating lymphocytes activated by Olvi-Vec. RNA profiling analysis identified expression of genes in tumors that were down-regulated or up-regulated after Olvi-Vec treatment. These transcriptional changes suggest four biologically relevant expression patterns associated with immune activation, viral infection, sensitization to chemotherapy, anticancer activity and survival. Combination therapy of Olvi-Vec and platinum-doublet chemotherapy resulted in a clinically meaningful benefit in the VIRO-15 study, reversing the typical trend of deteriorating PFS, and with clinical reversal of platinum resistance. Conclusion: Olvi-Vec treatment can favorably modify the TME in OC and may explain the apparent reversal of platinum resistance following platinum rechallenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.